Page last updated: 2024-11-12
bencycloquidium bromide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bencycloquidium bromide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11531643 |
| CHEMBL ID | 4560341 |
| MeSH ID | M0508230 |
Synonyms (8)
| Synonym |
|---|
| 860804-18-8 |
| bencycloquidium bromide |
| 3-(2-cyclopentyl-2-hydroxy-2-phenylethoxy)-1-methylquinuclidin-1-ium bromide |
| CHEMBL4560341 , |
| bdbm50528213 |
| 1-cyclopentyl-2-[(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)oxy]-1-phenylethanol;bromide |
| 1-azoniabicyclo[2.2.2]octane, 3-(2-cyclopentyl-2-hydroxy-2-phenylethoxy)-1-methyl-, bromide (1:1) |
| AKOS040747943 |
Research Excerpts
Overview
Bencycloquidium bromide is a novel inhaled anticholinergic bronchodilator with high selectivity for muscarinic M3 receptor. It is under development for the treatment of rhinorrhea in rhinitis.
Toxicity
Pharmacokinetics
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical trial was comprised of the following four studies: (i) an open-label, single-dose escalation study to evaluate the safety and tolerability in healthy subjects after intranasal doses of BCQB ranging from 45 to 450 μg (total of six doses); (ii) an open-label, multiple-dose escalation study to assess the safety and tolerability in healthy subjects after intranasal administration with 120 and 150 μg doses of BCQB (360 and 450 μg/day) administered three times daily for 15 days; (iii) a randomized, open-label and parallel-group design to evaluate the single-dose pharmacokinetics of BCQB after intranasal dosing (45, 90, and 180 μg); and (iv) ten subjects received 120 μg of BCQB by intranasal administration, three times daily for 5 days with a final single dose on day 7 to assess its multiple-dose pharmacokinetics." | ( Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study. Chen, X; Ding, L; Ou, N; Sun, L; Sun, W; Wang, Y; Yan, Z; Zhang, H; Zhou, W, 2012) | 0.64 |
| " During the multiple dosing, the steady state was achieved within 3 days of 120 μg three times daily dosing of BCQB." | ( Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study. Chen, X; Ding, L; Ou, N; Sun, L; Sun, W; Wang, Y; Yan, Z; Zhang, H; Zhou, W, 2012) | 0.64 |
| " A slight accumulation of BCQB following multiple dosing was observed." | ( Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study. Chen, X; Ding, L; Ou, N; Sun, L; Sun, W; Wang, Y; Yan, Z; Zhang, H; Zhou, W, 2012) | 0.64 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.0062 | 0.0000 | 0.6902 | 10.0000 | AID1607601 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (13)
Molecular Functions (3)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled acetylcholine receptor activity | Muscarinic acetylcholine receptor M2 | Homo sapiens (human) |
| arrestin family protein binding | Muscarinic acetylcholine receptor M2 | Homo sapiens (human) |
| G protein-coupled serotonin receptor activity | Muscarinic acetylcholine receptor M2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (13)
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1607601 | Inhibition of M2 receptor (unknown origin) | 2019 | Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13 | Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (22.22%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (72.22%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||